New app aims to keep patients on Weight-Loss drugs longer
NCT ID NCT07216651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a web-based tool called WeDosify that helps doctors manage dosing of the weight-loss drug semaglutide for adults with overweight or obesity. Twenty participants who had recently started semaglutide used the tool over three months. The main goal was to see how many people stayed on the medication without stopping.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amarillo Premier Research (an Objective Health Partnership)
Amarillo, Texas, 37067, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fiber gummies: a tasty new weapon against obesity?
- Can a diabetes drug improve joint replacement outcomes?
- Can a new pill help older adults lose weight without losing strength?
- Can one avocado a day sharpen the aging brain?
- Can a strict diet put type 2 diabetes into remission?
- Can Weight-Loss surgery alter how medications work?